BMO Capital reiterates Outperform rating on Pfizer stock at $30 price target
PositiveFinancial Markets

BMO Capital has reaffirmed its Outperform rating on Pfizer's stock, setting a price target of $30. This endorsement highlights the firm's confidence in Pfizer's potential for growth, especially as the company continues to innovate in the pharmaceutical sector. Investors may find this news encouraging as it suggests a positive outlook for Pfizer's future performance.
— Curated by the World Pulse Now AI Editorial System